Spanish Red Biotech Pipeline

Oryzon

Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor

Type: Biodrugs/ Drugs
Therapeutic area:
Indication: Kabuki Syndrome Clinical Trial "HOPE" - in preparation IND 1H22 / FPI 1H22
Phase: 2Phase II, 1Phase I, 2Regulatory Preclinical, 1Non Regulatory Preclinical